TrialThe Journal of antimicrobial chemotherapy2021

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.

Saye H Khoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.